Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amid Brexit Chaos, UK PM Promises More R&D Funding, Lower Taxes, And Other Pro-Innovation Measures

Executive Summary

The UK prime minister has promised more government R&D funding and other incentives in an attempt to reassure businesses worried by the uncertainty created by the Brexit vote. The move comes shortly before the Chancellor’s autumn statement and the next meeting of the UK EU Life Sciences Steering Group.

You may also be interested in...

UK Industry Welcomes R&D Measures In Chancellor’s Autumn Statement

Faced with a predicted sharp decline in economic growth as a result of the Brexit vote, the UK Chancellor of the Exchequer has fleshed out proposals for supporting R&D and innovation that have been welcomed by the biopharmaceutical industry.

Brexit Minister Says ‘No’ To UK Staying In EU Drug Regulatory Framework

Liam Fox, one of the ministers in charge of leading the UK out of the EU, does not want the country to stay within the wider European drug regulatory system, even though many in the life science sector see this as vital if regulatory divergence and drug marketing delays are to be avoided.

Guido Rasi - The Face Of The EMA For A Decade

The head of the European Medicines Agency is nearing the end of his tenure. We consider Guido Rasi’s achievements over the past 10 years as well as the controversies that have arisen under his leadership – and report that sailing is likely to figure in his plans for life after the agency.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts